TIDMASM
07 October 2009, London, UK, and Cambridge, MA: Cancer drug
developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that
two Non-Executive Directors of Antisoma have taken all or part of
their fees for the quarter ended 30 September 2009 in ordinary shares
pursuant to resolutions of the Board of Directors dated 14 September
2004 and subsequently.
The new ordinary shares were issued at a price of 35.25 pence per
share, this being the mid-market closing price on the last trading
day of the quarter (30 September 2009). The relevant Directors have
agreed not to dispose of the shares allotted for a minimum period of
one year.
The allotment and total holdings following this allotment are shown
below.
Director Allotted Total Percentage of
issued
07 Oct holding ordinary shares
09
Michael Pappas 12,411 915,220 0.15%
Michael Lewis 24,823 154,263 0.03%
Application will be made to the London Stock Exchange and the UK
Listing Authority for the admission of the new ordinary shares of 1p
each. The total number of ordinary shares in the Company in issue and
admitted to the Official List following the above allotments will be
615,277,458.
The new ordinary shares will rank pari passu with the Company's
existing ordinary shares.
Enquiries:
Alison Saville, Senior Marketing and Communications Executive
Antisoma plc
+44 (0)20 3249 2144
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company
that develops novel products for the treatment of cancer. The Company
has operations in the UK and the US. Please visit www.antisoma.com
for further information about Antisoma.
=--END OF MESSAGE---
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
|